The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.

Authors

Rui-Hang Du, Yi Cheng, Zi-Peng Ren, Shu Li, Bo-Wen Yuan, Xiao-Nan Wei, Si-Yuan Yan

Published in

Molecular biology reports. Volume 53. Issue 1. Sep 18, 2026. Epub Sep 18, 2026.

Abstract

Chaperonin Containing TCP1 Subunit 6A (CCT6A), a structurally conserved core subunit of the eukaryotic CCT/TRiC complex, orchestrates ATP-dependent protein folding, cytoskeletal dynamics, and stress-responsive adaptation, reflecting its indispensable role in cellular homeostasis. Emerging evidence highlights CCT6A as a multifaceted oncogenic driver across diverse malignancies (such as colorectal cancer and hepatocellular carcinoma), through metabolic reprogramming, stabilization of oncoproteins, and immunosuppression. Its overexpression correlates with aggressive phenotypes, therapeutic resistance, and poor prognosis, positioning it as a robust diagnostic and prognostic biomarker. Beyond oncology, CCT6A also contributes to autoimmune diseases, pulmonary fibrosis, and acute kidney injury. Despite its therapeutic potential, key challenges include unresolved context-dependent signaling mechanisms, absence of subunit-specific inhibitors, and the need to reconcile CCT6A targeting with preservation of CCT complex functionality. This review delineates CCT6A's multifunctional roles in oncogenesis and immune-metabolic dysregulation, critically evaluates its biomarker potential, and proposes targeted therapeutic frameworks to refine precision medicine paradigms across diverse disease landscapes.

PMID:
42758405
Bibliographic data and abstract were imported from PubMed on 19 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.